Last updated on December 2018

S1415CD Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Stage 0 Colorectal Cancer | Stage IIIB Colorectal Cancer | Stage IIA Colorectal Cancer | Stage IIIA Breast Cancer | Stage 0 Non-Small Cell Lung Cancer | Stage IIB Breast Cancer | Stage IVA Colorectal Cancer | Stage IIC Colorectal Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Stage 0 Breast Cancer | Stage IIA Breast Cancer | Stage IIIB Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage IIIC Colorectal Cancer | Stage IIB Non-Small Cell Lung Carcinoma | Stage IIB Colorectal Cancer | Febrile Neutropenia | Stage IV Breast Cancer | Stage IVB Colorectal Cancer | Stage I Colorectal Cancer | Stage IB Breast Cancer | Stage IIIA Colorectal Cancer | Stage IIIA Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung Carcinoma | Stage IA Breast Cancer
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Patients must have a current diagnosis of breast cancer, non-small cell lung cancer, or colorectal cancer; cancer may be metastatic or non-metastatic
  • Patients must be planning to receive one of the study-allowed regimens as their initial treatment for their current diagnosis
  • Patients must be registered prior to their first cycle of systemic therapy (chemotherapy, immunotherapy, biologic therapy, or combination regimens) for this diagnosis; if patient has had any prior systemic therapy for another malignancy, patient must not have had any systemic therapy in the 180 days just prior to registration
  • Patients must not have any known contraindication to CSFs prior to registration, including prior hypersensitivity to Escherichia coli-derived proteins, filgrastim, pegfilgrastim, or tbo-filgrastim
  • Patients must be able to understand and provide information for the patient-completed study forms in either English or Spanish
  • Patients may have had a prior malignancy
  • Patients must not be participating or plan to participate in other clinical trials that involve investigational systemic cancer treatments or investigational uses of CSF
  • Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
  • As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.